文献速递MDS 与骨髓增殖性肿瘤白血病

口服地西他滨-西达尿苷与静脉地西他滨治疗骨髓增生异常综合征和慢性粒-单核细胞白血病的比较(ASCERTAIN):一项注册性、随机、交叉、药代动力学、3期研究

Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.
PubMed 文献 · Lancet Haematol · 2024-01-01

ASCERTAIN研究在加拿大和美国的37家学术和社区诊所纳入133例骨髓增生异常综合征或慢性粒-单核细胞白血病患者,随机交叉接受口服地西他滨-西达尿苷或静脉地西他滨5天方案。主要终点5天地西他滨总暴露量比值98.93%(90%CI 92.66-105.60),表明两者药代动力学等效,安全谱相似。

要点

  • 口服地西他滨-西达尿苷与静脉地西他滨5天总暴露量比值98.93%(90%CI 92.66-105.60),药代动力学等效。
  • 两组安全谱相似;最常见的3级及以上不良事件为血小板减少(61%)、中性粒细胞减少(57%)和贫血(50%)。
  • 第1-2周期严重不良事件发生率口服组31% vs 静脉组18%;治疗相关死亡5例(口服组2例,静脉组3例)。

核心结论

  • 口服地西他滨-西达尿苷在药理学和药效学上与静脉地西他滨等效。
  • 结果支持口服地西他滨-西达尿苷作为静脉地西他滨的安全有效替代方案,用于治疗骨髓增生异常综合征或慢性粒-单核细胞白血病患者。

研究设计与样本

  • 注册性、多中心、开放标签、交叉、3期试验,在加拿大和美国的37家学术和社区诊所进行。
  • 纳入年龄≥18岁、适合接受静脉地西他滨、ECOG体能状态0或1、预期寿命至少3个月的患者;骨髓增生异常综合征或慢性粒-单核细胞白血病患者与急性髓系白血病患者作为独立队列入组,本文仅报告骨髓增生异常综合征或慢性粒-单核细胞白血病患者结果。
  • 参与者按1:1随机分配至第1周期接受5天口服地西他滨-西达尿苷(每片含35 mg地西他滨和100 mg西达尿苷的固定剂量复方片,每日一次)或静脉地西他滨(20 mg/m2/日,连续1小时静脉输注),28天为一治疗周期,第2周期交叉接受另一制剂5天,此后从第3周期起所有参与者接受口服地西他滨-西达尿苷直至治疗终止。
  • 主要终点为第1和第2周期口服地西他滨-西达尿苷与静脉地西他滨5天地西他滨总暴露量(曲线下面积),在完整接受第1和第2周期治疗且具有两种制剂每日AUC0-24数据的参与者中评估。
  • 2018年2月8日至2021年6月7日筛查173人,138人(80%)随机分配至治疗序列,133人(96%)接受治疗(87例[65%]男性,46例[35%]女性;121例[91%]白人,4例[3%]黑人或非裔美国人,3例[2%]亚裔,5例[4%]未报告);中位随访966天(IQR 917-1050)。

主要发现

  • 主要终点口服地西他滨-西达尿苷与静脉地西他滨5天总暴露量比值为98.93%(90%CI 92.66-105.60),基于曲线下面积表明药代动力学暴露等效。
  • 口服地西他滨-西达尿苷与静脉地西他滨的安全谱相似。
  • 最常见的3级及以上不良事件为血小板减少(81/133例,61%)、中性粒细胞减少(76/133例,57%)和贫血(67/133例,50%)。
  • 第1-2周期严重不良事件发生率:口服地西他滨-西达尿苷组31%(40/130例),静脉地西他滨组18%(24/132例)。
  • 治疗相关死亡5例:2例被认为与口服治疗相关(败血症和肺炎),3例与静脉治疗相关(感染性休克2例,肺炎1例)。

关键数值与推荐

  • 口服地西他滨-西达尿苷固定剂量复方片每片含35 mg地西他滨和100 mg西达尿苷,每日一次,每28天周期用5天。
  • 静脉地西他滨剂量为20 mg/m2/日,连续1小时静脉输注,每28天周期用5天。
  • 主要终点等效性判断基于5天地西他滨总暴露量(AUC)比值90%CI落在预设等效范围内。

临床怎么用

  • 作者结论认为结果支持口服地西他滨-西达尿苷作为静脉地西他滨的安全有效替代方案,用于治疗骨髓增生异常综合征或慢性粒-单核细胞白血病患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The DNA methyltransferase inhibitors azacitidine and decitabine for individuals with myelodysplastic syndromes or chronic myelomonocytic leukaemia are available in parenteral form. Oral therapy with similar exposure for these diseases would offer potential treatment benefits. We aimed to compare the safety and pharmacokinetics of oral decitabine plus the cytidine deaminase inhibitor cedazuridine versus intravenous decitabine. METHODS: We did a registrational, multicentre, open-label, crossover, phase 3 trial of individuals with myelodysplastic syndromes or chronic myelomonocytic leukaemia and individuals with acute myeloid leukaemia, enrolled as separate cohorts; results for only participants with myelodysplastic syndromes or chronic myelomonocytic leukaemia are reported here. In 37 academic and community-based clinics in Canada and the USA, we enrolled individuals aged 18 years or older who were candidates to receive intravenous decitabine, with Eastern Cooperative Oncology Group performance status 0 or 1 and a life expectancy of at least 3 months. Participants were randomly assigned (1:1) to receive 5 days of oral decitabine-cedazuridine (one tablet once daily containing 35 mg decitabine and 100 mg cedazuridine as a fixed-dose combination) or intravenous decitabine (20 mg/m2 per day by continuous 1-h intravenous infusion) in a 28-day treatment cycle, followed by 5 days of the other formulation in the next treatment cycle. Thereafter, all participants received oral decitabine-cedazuridine from the third cycle on until treatment discontinuation. The primary endpoint was total decitabine exposure over 5 days with oral decitabine-cedazuridine versus intravenous decitabine for cycles 1 and 2, measured as area under the curve in participants who received the full treatment dose in cycles 1 and 2 and had decitabine daily AUC0-24 for both oral decitabine-cedazuridine and intravenous decitabine (ie, paired cycles). On completion of the study, all patients were rolled over to a maintenance study. This study is registered with ClinicalTrials.gov, NCT03306264. FINDINGS: Between Feb 8, 2018, and June 7, 2021, 173 individuals were screened, 138 (80%) participants were randomly assigned to a treatment sequence, and 133 (96%) participants (87 [65%] men and 46 [35%] women; 121 [91%] White, four [3%] Black or African-American, three [2%] Asian, and five [4%] not reported) received treatment. Median follow-up was 966 days (IQR 917-1050). Primary endpoint of total exposure of oral decitabine-cedazuridine versus intravenous decitabine was 98·93% (90% CI 92·66-105·60), indicating equivalent pharmacokinetic exposure on the basis of area under the curve. The safety profiles of oral decitabine-cedazuridine and intravenous decitabine were similar. The most frequent adverse events of grade 3 or worse were thrombocytopenia (81 [61%] of 133 participants), neutropenia (76 [57%] participants), and anaemia (67 [50%] participants). The incidence of serious adverse events in cycles 1-2 was 31% (40 of 130 participants) with oral decitabine-cedazuridine and 18% (24 of 132 participants) with intravenous decitabine. There were five treatment-related deaths; two deemed related to oral therapy (sepsis and pneumonia) and three to intravenous treatment (septic shock [n=2] and pneumonia [n=1]). INTERPRETATION: Oral decitabine-cedazuridine was pharmacologically and pharmacodynamically equivalent to intravenous decitabine. The results support use of oral decitabine-cedazuridine as a safe and effective alternative to intravenous decitabine for treatment of individuals with myelodysplastic syndromes or chronic myelomonocytic leukaemia. FUNDING: Astex Pharmaceuticals.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Garcia-Manero G, McCloskey J, Griffiths EA, et al. Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. Lancet Haematol. 2024. PMID: 38135371. doi:10.1016/S2352-3026(23)00338-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。